Phase II trial of Epirubicin / Cyclophosphamide (EC) followed by Nab-paclitaxel as neoadjuvant chemotherapy for node positive breast cancer
Phase 2
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000009853
- Lead Sponsor
- Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 23
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of sever hypersensitivity 2) Active other malignancies 3) Severe complications (infection, uncontrolled diabetes mellitus, uncontrolled angina, heart infarction within 6 months, heart failure etc.) 4) has psychological illness which became a problem in practice 5) sever bone suppression, renal dysfunction, and liver dysfunction 6) sever pleural effusion or ascites fluid 7) has infection or fever which suspected of infection 8) pregnant or possibility of pregnant 9) Patients judged inappropriate by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method